Although ophthalmologists don’t have to join an ACO, new referral patterns could have a marked effect on them. Medscape Ophthalmology
ROLL study: Ranibizumab to aflibercept treatment change yields stable visual acuity results
MIAMI — Vision remained stable in patients whose treatment was changed from ranibizumab to aflibercept, but vascularized pigment epithelial detachments continue to be difficult to treat, a researcher reporting 6-month results of the ROLL study said here. The ROLL trial was initiated when the HiPED trial — an investigator-sponsored trial studying 2 mg Lucentis (ranibizumab, Genentech) in patients with neovascular age-related macular degeneration with recalcitrant fibrovascular pigment epithelial detachment (PED) — was terminated early because the 2 mg dose was no longer available.
Computer models help decode cells that sense light without seeing
Researchers have found that the melanopsin pigment in the eye is potentially more sensitive to light than its more famous counterpart, rhodopsin, the pigment that allows for night vision.
How ACOs Will Affect Ophthalmologists
iTunes conversion to RSS provided by Feed Flipper: [Web] – [Facebook] – [Donate!]
Although ophthalmologists don’t have to join an ACO, new referral patterns could have a marked effect on them.
Vibrostimulation for Olympic Victory: That’s Improbable!
(MedPage Today) — A weekly report from our friends at Improbable Research.
Outcomes of Corneal Collagen Crosslinking Treatment
How successful is corneal crosslinking treatment in patients with progressive keratoconus, and what are some of the factors that could influence outcomes? Eye